The DOI matches its Crossref record; 173 of the 173 references it cites were found in a registry or an index.
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Open accessAbstract
SUMMARY The success of immune checkpoint blockade in patients with a wide variety of malignancies has changed the treatment paradigm in oncology. However, combination therapies with immune checkpoint blockade will be needed to overcome resistance and broaden the clinical utility of immunotherapy. Here we discuss a framework for rationally designing combination therapy strategies based on enhancing major discriminatory functions of the immune system that are corrupted by cancer – namely, antigenicity, adjuvanticity, and homeostatic feedback inhibition. We review recent advances on how conventional genotoxic cancer therapies, molecularly targeted therapies, epigenetic agents, and immune checkpoint inhibitors can restore these discriminatory functions. Potential barriers that can impede response despite combination therapy are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Epithelial-Mesenchymal Transitions in Development and Disease
Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009) · Cell · doi:10.1016/j.cell.2009.11.007 · Cited by 9,931
Pattern Recognition Receptors and Inflammation
Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Immunobiology of Dendritic Cells
Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y.-J., Pulendran, B., & Palucka, K. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.767 · Cited by 6,634
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 2×
“…the nature of the immune infiltration in the tumor (Coussens et al., 2013), expression of PD-L1 on tumor and immune cells (Herbst et al., 2014; Tumeh et al., 2014), and developmental fate of T cells (Pauken and Wherry, 2015), are just some of the tumor cell extrinsic factors that influence…”
BackgroundTGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Self-citationTumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Riaz, N., Havel, J. J., Makarov, V., Desrichard, A., Urba, W. J., Sims, J. S., Hodi, F. S., Martín-Algarra, S., Mandal, R., Sharfman, W. H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.028 · Cited by 2,401 · cited 2×
“After start of therapy, tumors responding to anti-PD-1 show loss of predicted neo-antigens and contraction of the subclones that express them (Riaz et al., 2017).”
BackgroundRegulation and function of the cGAS–STING pathway of cytosolic DNA sensing
Chen, Q., Sun, L., & Chen, Z. J. (2016) · Nature Immunology · doi:10.1038/ni.3558 · Cited by 2,333
Nasir, O. (2013) · Kidney and Blood Pressure Research · doi:10.1159/000350152 · Cited by 2,331
Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182
Control of adaptive immunity by the innate immune system
Iwasaki, A., & Medzhitov, R. (2015) · Nature Immunology · doi:10.1038/ni.3123 · Cited by 2,160 · cited 1×
“Conceptually, these discriminatory functions likely evolved to balance the “cost” associated with immune effector responses – specifically, direct detrimental effects of pathogens versus immunopathology from excessive immune stimulation (Iwasaki and Medzhitov, 2015).”
BackgroundTaube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Postow, M. A., Callahan, M. K., Barker, C. A., Yamada, Y., Yuan, J., Kitano, S., Mu, Z., Rasalan, T., Adamow, M., Ritter, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112824 · Cited by 2,087
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Im, S. J., Hashimoto, M., Gerner, M. Y., Lee, J., Kissick, H. T., Burger, M. C., Shan, Q., Hale, J. S., Lee, J., Nasti, T. H., et al. (2016) · Nature · doi:10.1038/nature19330 · Cited by 2,070
Blackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062
Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.011 · Cited by 2,022
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851
DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
Vanpouille-Box, C., Alard, A., Aryankalayil, M. J., Sarfraz, Y., Diamond, J. M., Schneider, R. J., Inghirami, G., Coleman, C. N., Formenti, S. C., & Demaria, S. (2017) · Nature Communications · doi:10.1038/ncomms15618 · Cited by 1,834
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
cGAS surveillance of micronuclei links genome instability to innate immunity
Mackenzie, K. J., Carroll, P., Martin, C.-A., Murina, O., Fluteau, A., Simpson, D. J., Olova, N., Sutcliffe, H., Rainger, J. K., Leitch, A., et al. (2017) · Nature · doi:10.1038/nature23449 · Cited by 1,752
Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737
IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis
Coffelt, S. B., Kersten, K., Doornebal, C. W., Weiden, J., Vrijland, K., Hau, C.-S., Verstegen, N. J. M., Ciampricotti, M., Hawinkels, L. J. A. C., Jonkers, J., et al. (2015) · Nature · doi:10.1038/nature14282 · Cited by 1,703
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Huang, A. C., Postow, M. A., Orlowski, R. J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J. R., Wenz, B., et al. (2017) · Nature · doi:10.1038/nature22079 · Cited by 1,664
Koyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10501 · Cited by 1,580
Corrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., Woo, S.-R., Lemmens, E., Banda, T., Leong, J. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.031 · Cited by 1,560
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
Roulois, D., Loo Yau, H., Singhania, R., Wang, Y., Danesh, A., Shen, S. Y., Han, H., Liang, G., Jones, P. A., Pugh, T. J., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.056 · Cited by 1,527
Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy
Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.027 · Cited by 1,520
CDK4/6 inhibition triggers anti-tumour immunity
Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature · doi:10.1038/nature23465 · Cited by 1,513
Mitotic progression following DNA damage enables pattern recognition within micronuclei
Harding, S. M., Benci, J. L., Irianto, J., Discher, D. E., Minn, A. J., & Greenberg, R. A. (2017) · Nature · doi:10.1038/nature23470 · Cited by 1,508
Self-citationSpranger, S., Dai, D., Horton, B., & Gajewski, T. F. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.003 · Cited by 1,441
Langer, C. J., Gadgeel, S. M., Borghaei, H., Papadimitrakopoulou, V. A., Patnaik, A., Powell, S. F., Gentzler, R. D., Martins, R. G., Stevenson, J. P., Jalal, S. I., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30498-3 · Cited by 1,404
Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade
Pauken, K. E., Sammons, M. A., Odorizzi, P. M., Manne, S., Godec, J., Khan, O., Drake, A. M., Chen, Z., Sen, D. R., Kurachi, M., et al. (2016) · Science · doi:10.1126/science.aaf2807 · Cited by 1,348 · cited 3×
“Consistent with the notion that lack of epigenetic plasticity limits the reversal of T cell exhaustion, TEX do not develop into memory T cells (TMEM) after PD-1 blockade but instead re-exhaust (Pauken et al., 2016).”
BackgroundCytoplasmic chromatin triggers inflammation in senescence and cancer
Dou, Z., Ghosh, K., Vizioli, M. G., Zhu, J., Sen, P., Wangensteen, K. J., Simithy, J., Lan, Y., Lin, Y., Zhou, Z., et al. (2017) · Nature · doi:10.1038/nature24050 · Cited by 1,335
Zhu, Y., Knolhoff, B. L., Meyer, M. A., Nywening, T. M., West, B. L., Luo, J., Wang-Gillam, A., Goedegebuure, S. P., Linehan, D. C., & DeNardo, D. G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3723 · Cited by 1,324
Lee, Y., Auh, S. L., Wang, Y., Burnette, B., Wang, Y., Meng, Y., Beckett, M., Sharma, R., Chin, R., Tu, T., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206870 · Cited by 1,324
Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302 · cited 2×
“These two immune checkpoints are thought to be largely nonredundant both spatiotemporally and in their immune effects (Topalian et al., 2015; Wei et al., 2017); however, recent interactions through CD28 have been uncovered that implicate potentially more mechanistic overlap than previously appreciated (Kamphorst et al.”
BackgroundLoss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy
Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Matsushita, H., Vesely, M. D., Koboldt, D. C., Rickert, C. G., Uppaluri, R., Magrini, V. J., Arthur, C. D., White, J. M., Chen, Y.-S., Shea, L. K., et al. (2012) · Nature · doi:10.1038/nature10755 · Cited by 1,288
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Benci, J. L., Xu, B., Qiu, Y., Wu, T. J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D. S. M., Pauken, K. E., Huang, A. C., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.022 · Cited by 1,216
Self-citationEpigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. (2015) · Nature · doi:10.1038/nature15520 · Cited by 1,201
Salmon, H., Idoyaga, J., Rahman, A., Leboeuf, M., Remark, R., Jordan, S., Casanova-Acebes, M., Khudoynazarova, M., Agudo, J., Tung, N., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.03.012 · Cited by 1,201
Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence
Glück, S., Guey, B., Gulen, M. F., Wolter, K., Kang, T.-W., Schmacke, N. A., Bridgeman, A., Rehwinkel, J., Zender, L., & Ablasser, A. (2017) · Nature Cell Biology · doi:10.1038/ncb3586 · Cited by 1,196 · cited 1×
“Indeed, cGAS has a more general role in inflammation after tissue damage and in immunosurveillance against cancer (Dou et al., 2017; Glück et al., 2017).”
BackgroundHirano, T., Ishihara, K., & Hibi, M. (2000) · Oncogene · doi:10.1038/sj.onc.1203551 · Cited by 1,190
Immunogenic and tolerogenic cell death
Green, D. R., Ferguson, T., Zitvogel, L., & Kroemer, G. (2009) · Nature Reviews Immunology · doi:10.1038/nri2545 · Cited by 1,176
PI3Kγ is a molecular switch that controls immune suppression
Kaneda, M. M., Messer, K. S., Ralainirina, N., Li, H., Leem, C. J., Gorjestani, S., Woo, G., Nguyen, A. V., Figueiredo, C. C., Foubert, P., et al. (2016) · Nature · doi:10.1038/nature19834 · Cited by 1,173
Overcoming T cell exhaustion in infection and cancer
Pauken, K. E., & Wherry, E. J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.008 · Cited by 1,171
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Manguso, R. T., Pope, H. W., Zimmer, M. D., Brown, F. D., Yates, K. B., Miller, B. C., Collins, N. B., Bi, K., LaFleur, M. W., Juneja, V. R., et al. (2017) · Nature · doi:10.1038/nature23270 · Cited by 1,147
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,111
Utzschneider, D. T., Charmoy, M., Chennupati, V., Pousse, L., Ferreira, D. P., Calderon-Copete, S., Danilo, M., Alfei, F., Hofmann, M., Wieland, D., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.021 · Cited by 1,085
The Principles of Engineering Immune Cells to Treat Cancer
Lim, W. A., & June, C. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.016 · Cited by 1,080
Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?
Coussens, L. M., Zitvogel, L., & Palucka, A. K. (2013) · Science · doi:10.1126/science.1232227 · Cited by 1,079
Demaria, S., Kawashima, N., Yang, A. M., Devitt, M. L., Babb, J. S., Allison, J. P., & Formenti, S. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.728.11.2 · Cited by 1,022
Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
Kamphorst, A. O., Wieland, A., Nasti, T., Yang, S., Zhang, R., Barber, D. L., Konieczny, B. T., Daugherty, C. Z., Koenig, L., Yu, K., et al. (2017) · Science · doi:10.1126/science.aaf0683 · Cited by 1,015
Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., et al. (2018) · Nature · doi:10.1038/nature25015 · Cited by 1,013
Ruffell, B., Chang-Strachan, D., Chan, V., Rosenbusch, A., Ho, C. M. T., Pryer, N., Daniel, D., Hwang, E. S., Rugo, H. S., & Coussens, L. M. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.006 · Cited by 1,008
The epigenetic landscape of T cell exhaustion
Sen, D. R., Kaminski, J., Barnitz, R. A., Kurachi, M., Gerdemann, U., Yates, K. B., Tsao, H.-W., Godec, J., LaFleur, M. W., Brown, F. D., et al. (2016) · Science · doi:10.1126/science.aae0491 · Cited by 986
Apoptotic Caspases Suppress mtDNA-Induced STING-Mediated Type I IFN Production
White, M. J., McArthur, K., Metcalf, D., Lane, R. M., Cambier, J. C., Herold, M. J., van Delft, M. F., Bedoui, S., Lessene, G., Ritchie, M. E., et al. (2014) · Cell · doi:10.1016/j.cell.2014.11.036 · Cited by 983 · cited 1×
“Moreover, the immunologically silent nature of apoptosis is maintained by Caspasemediated inactivation of Bax, preventing the release of mitochondrial DNA and subsequent activation of the endoplasmic reticulum associated signaling protein STING (Rongvaux et al., 2014; White et al., 2014).”
BackgroundUnderstanding and targeting resistance mechanisms in NSCLC
Rotow, J., & Bivona, T. G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.84 · Cited by 972
Chen, L., Gibbons, D. L., Goswami, S., Cortez, M. A., Ahn, Y.-H., Byers, L. A., Zhang, X., Yi, X., Dwyer, D., Lin, W., et al. (2014) · Nature Communications · doi:10.1038/ncomms6241 · Cited by 966
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Pfirschke, C., Engblom, C., Rickelt, S., Cortez-Retamozo, V., Garris, C., Pucci, F., Yamazaki, T., Poirier-Colame, V., Newton, A., Redouane, Y., et al. (2016) · Immunity · doi:10.1016/j.immuni.2015.11.024 · Cited by 952
Chromatin states define tumour-specific T cell dysfunction and reprogramming
Philip, M., Fairchild, L., Sun, L., Horste, E. L., Camara, S., Shakiba, M., Scott, A. C., Viale, A., Lauer, P., Merghoub, T., et al. (2017) · Nature · doi:10.1038/nature22367 · Cited by 933 · cited 8×
“Similarly, DNMTi combined with a HDACi decreases exhaustion-associated genes expressed by TILs in a lung adenocarcinoma model (Topper et al., 2017).”
BackgroundInfluentialER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis
Cubillos-Ruiz, J. R., Silberman, P. C., Rutkowski, M. R., Chopra, S., Perales-Puchalt, A., Song, M., Zhang, S., Bettigole, S. E., Gupta, D., Holcomb, K., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.025 · Cited by 933
Coinhibitory Pathways in Immunotherapy for Cancer
Baumeister, S. H., Freeman, G. J., Dranoff, G., & Sharpe, A. H. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112049 · Cited by 910
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
De Henau, O., Rausch, M., Winkler, D., Campesato, L. F., Liu, C., Cymerman, D. H., Budhu, S., Ghosh, A., Pink, M., Tchaicha, J., et al. (2016) · Nature · doi:10.1038/nature20554 · Cited by 860
Kamphorst, A. O., Pillai, R. N., Yang, S., Nasti, T. H., Akondy, R. S., Wieland, A., Sica, G. L., Yu, K., Koenig, L., Patel, N. T., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705327114 · Cited by 854
Apoptotic Caspases Prevent the Induction of Type I Interferons by Mitochondrial DNA
Rongvaux, A., Jackson, R., Harman, C. C. D., Li, T., West, A. P., de Zoete, M. R., Wu, Y., Yordy, B., Lakhani, S. A., Kuan, C.-Y., et al. (2014) · Cell · doi:10.1016/j.cell.2014.11.037 · Cited by 847
Purinergic regulation of the immune system
Cekic, C., & Linden, J. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.4 · Cited by 787
De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation
Ghoneim, H. E., Fan, Y., Moustaki, A., Abdelsamed, H. A., Dash, P., Dogra, P., Carter, R., Awad, W., Neale, G., Thomas, P. G., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.007 · Cited by 781
Role of Local Radiation Therapy in Cancer Immunotherapy
Demaria, S., Golden, E. B., & Formenti, S. C. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2756 · Cited by 779
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Deng, J., Wang, E. S., Jenkins, R. W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A. R., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0915 · Cited by 770
Persistent LCMV infection is controlled by blockade of type I interferon signaling
Teijaro, J. R., Ng, C., Lee, A. M., Sullivan, B. M., Sheehan, K. C. F., Welch, M., Schreiber, R. D., Carlos de la Torre, J., & Oldstone, M. B. A. (2013) · Science · doi:10.1126/science.1235214 · Cited by 755 · cited 1×
“…in the LCMV model at later times after chronic infection is established can decrease viral titers and improve chronic infection, indicating that chronic IFN signaling contributes to immune suppression and persistent infection (Sandler et al., 2014; Teijaro et al., 2013; Wilson et al., 2013).”
BackgroundSchietinger, A., Philip, M., Krisnawan, V. E., Chiu, E. Y., Delrow, J. J., Basom, R. S., Lauer, P., Brockstedt, D. G., Knoblaugh, S. E., Hämmerling, G. J., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.011 · Cited by 720 · cited 1×
“As previously discussed, TEX adopt an inflexible epigenetic state that is distinct from effector or memory T cells (Figure 4), and this dysfunction may occur early during tumorigenesis (Pauken et al., 2016; Philip et al., 2017; Schietinger et al., 2016; Sen et al., 2016).”
BackgroundSTING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
Fu, J., Kanne, D. B., Leong, M., Glickman, L. H., McWhirter, S. M., Lemmens, E., Mechette, K., Leong, J. J., Lauer, P., Liu, W., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4306 · Cited by 720
Härtlova, A., Erttmann, S. F., Raffi, F. A., Schmalz, A. M., Resch, U., Anugula, S., Lienenklaus, S., Nilsson, L. M., Kröger, A., Nilsson, J. A., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.01.012 · Cited by 716 · cited 1×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript damage, regulates PRR activation and early IFN-I signaling that can influence viral and bacterial defense (Härtlova et al., 2015; Purbey et al., 2017).”
BackgroundVISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
Wang, L., Rubinstein, R., Lines, J. L., Wasiuk, A., Ahonen, C., Guo, Y., Lu, L.-F., Gondek, D., Wang, Y., Fava, R. A., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100619 · Cited by 710
Blockade of chronic type I interferon signaling to control persistent LCMV infection
Wilson, E. B., Yamada, D. H., Elsaesser, H., Herskovitz, J., Deng, J., Cheng, G., Aronow, B. J., Karp, C. L., & Brooks, D. G. (2013) · Science · doi:10.1126/science.1235208 · Cited by 709
Juergens, R. A., Wrangle, J., Vendetti, F. P., Murphy, S. C., Zhao, M., Coleman, B., Sebree, R., Rodgers, K., Hooker, C. M., Franco, N., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0214 · Cited by 686
Follicular CXCR5-expressing CD8+ T cells curtail chronic viral infection
He, R., Hou, S., Liu, C., Zhang, A., Bai, Q., Han, M., Yang, Y., Wei, G., Shen, T., Yang, X., et al. (2016) · Nature · doi:10.1038/nature19317 · Cited by 677
Dighe, A. S., Richards, E., Old, L. J., & Schreiber, R. D. (1994) · Immunity · doi:10.1016/1074-7613(94)90087-6 · Cited by 663
Discriminating self from non-self in nucleic acid sensing
Schlee, M., & Hartmann, G. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.78 · Cited by 593
Xia, T., Konno, H., Ahn, J., & Barber, G. N. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.029 · Cited by 589
Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape
Wellenstein, M. D., & de Visser, K. E. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.004 · Cited by 589
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity
Park, S., Jiang, Z., Mortenson, E. D., Deng, L., Radkevich-Brown, O., Yang, X., Sattar, H., Wang, Y., Brown, N. K., Greene, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.014 · Cited by 577
cGAS is essential for the antitumor effect of immune checkpoint blockade
Wang, H., Hu, S., Chen, X., Shi, H., Chen, C., Sun, L., & Chen, Z. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1621363114 · Cited by 563
Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages
Guerriero, J. L., Sotayo, A., Ponichtera, H. E., Castrillon, J. A., Pourzia, A. L., Schad, S., Johnson, S. F., Carrasco, R. D., Lazo, S., Bronson, R. T., et al. (2017) · Nature · doi:10.1038/nature21409 · Cited by 558 · cited 4×
“However, tumors that transition into mesenchymal states by inflammatory cytokines or oncogenic signals exhibit an immuneTME that excludes T cells and supports suppressive TAMs and MDSCs. Chronic cytokine signals such as IFN can exacerbate immune suppression through various mechanisms, which can contrast with their typ…”
BackgroundInfluentialDiscovery of IDO1 Inhibitors: From Bench to Bedside
Prendergast, G. C., Malachowski, W. P., DuHadaway, J. B., & Muller, A. J. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2285 · Cited by 558
Myc Cooperates with Ras by Programming Inflammation and Immune Suppression
Kortlever, R. M., Sodir, N. M., Wilson, C. H., Burkhart, D. L., Pellegrinet, L., Brown Swigart, L., Littlewood, T. D., & Evan, G. I. (2017) · Cell · doi:10.1016/j.cell.2017.11.013 · Cited by 553
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer
Topper, M. J., Vaz, M., Chiappinelli, K. B., DeStefano Shields, C. E., Niknafs, N., Yen, R.-W. C., Wenzel, A., Hicks, J., Ballew, M., Stone, M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.022 · Cited by 537
Mak, M. P., Tong, P., Diao, L., Cardnell, R. J., Gibbons, D. L., William, W. N., Skoulidis, F., Parra, E. R., Rodriguez-Canales, J., Wistuba, I. I., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0876 · Cited by 535
Expression of tumour-specific antigens underlies cancer immunoediting
DuPage, M., Mazumdar, C., Schmidt, L. M., Cheung, A. F., & Jacks, T. (2012) · Nature · doi:10.1038/nature10803 · Cited by 529
TGFβ is a master regulator of radiation therapy-induced antitumor immunity
Vanpouille-Box, C., Diamond, J. M., Pilones, K. A., Zavadil, J., Babb, J. S., Formenti, S. C., Barcellos-Hoff, M. H., & Demaria, S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3511 · Cited by 514
cGAS senses long and HMGB/TFAM-bound U-turn DNA by forming protein-DNA ladders
Andreeva, L., Hiller, B., Kostrewa, D., Lässig, C., de Oliveira Mann, C. C., Jan Drexler, D., Maiser, A., Gaidt, M., Leonhardt, H., Hornung, V., et al. (2017) · Nature · doi:10.1038/nature23890 · Cited by 511
Stagg, J., Loi, S., Divisekera, U., Ngiow, S. F., Duret, H., Yagita, H., Teng, M. W., & Smyth, M. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016569108 · Cited by 496
Regulation of antiviral T cell responses by type I interferons
Crouse, J., Kalinke, U., & Oxenius, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3806 · Cited by 479
Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression
Sandler, N. G., Bosinger, S. E., Estes, J. D., Zhu, R. T. R., Tharp, G. K., Boritz, E., Levin, D., Wijeyesinghe, S., Makamdop, K. N., del Prete, G. Q., et al. (2014) · Nature · doi:10.1038/nature13554 · Cited by 461
Jiménez-Sánchez, A., Memon, D., Pourpe, S., Veeraraghavan, H., Li, Y., Vargas, H. A., Gill, M. B., Park, K. J., Zivanovic, O., Konner, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.025 · Cited by 458
Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1
Vacchelli, E., Ma, Y., Baracco, E. E., Sistigu, A., Enot, D. P., Pietrocola, F., Yang, H., Adjemian, S., Chaba, K., Semeraro, M., et al. (2015) · Science · doi:10.1126/science.aad0779 · Cited by 452
Nabet, B. Y., Qiu, Y., Shabason, J. E., Wu, T. J., Yoon, T., Kim, B. C., Benci, J. L., DeMichele, A. M., Tchou, J., Marcotrigiano, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.031 · Cited by 452
Self-citationLou, Y., Diao, L., Cuentas, E. R. P., Denning, W. L., Chen, L., Fan, Y. H., Byers, L. A., Wang, J., Papadimitrakopoulou, V. A., Behrens, C., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1434 · Cited by 438
The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity
Moroishi, T., Hayashi, T., Pan, W.-W., Fujita, Y., Holt, M. V., Qin, J., Carson, D. A., & Guan, K.-L. (2016) · Cell · doi:10.1016/j.cell.2016.11.005 · Cited by 431
A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells
Singer, M., Wang, C., Cong, L., Marjanovic, N. D., Kowalczyk, M. S., Zhang, H., Nyman, J., Sakuishi, K., Kurtulus, S., Gennert, D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.052 · Cited by 420
Arce Vargas, F., Furness, A. J. S., Solomon, I., Joshi, K., Mekkaoui, L., Lesko, M. H., Miranda Rota, E., Dahan, R., Georgiou, A., Sledzinska, A., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.03.013 · Cited by 418
Ahrends, T., Spanjaard, A., Pilzecker, B., Bąbała, N., Bovens, A., Xiao, Y., Jacobs, H., & Borst, J. (2017) · Immunity · doi:10.1016/j.immuni.2017.10.009 · Cited by 413
Ultraviolet radiation damages self noncoding RNA and is detected by TLR3
Bernard, J. J., Cowing-Zitron, C., Nakatsuji, T., Muehleisen, B., Muto, J., Borkowski, A. W., Martinez, L., Greidinger, E. L., Yu, B. D., & Gallo, R. L. (2012) · Nature Medicine · doi:10.1038/nm.2861 · Cited by 407
Epithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomas
Dongre, A., Rashidian, M., Reinhardt, F., Bagnato, A., Keckesova, Z., Ploegh, H. L., & Weinberg, R. A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3292 · Cited by 395
5′-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma
Poeck, H., Besch, R., Maihoefer, C., Renn, M., Tormo, D., Morskaya, S. S., Kirschnek, S., Gaffal, E., Landsberg, J., Hellmuth, J., et al. (2008) · Nature Medicine · doi:10.1038/nm.1887 · Cited by 387 · cited 1×
“Direct introduction of RNA ligands to activate RIG-I in cancer models promotes an IFN-I response, DC activation, and stimulates innate and adaptive immune cells (Nabet et al., 2017; Poeck et al., 2008).”
BackgroundImmune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
Liu, J., Yuan, Y., Chen, W., Putra, J., Suriawinata, A. A., Schenk, A. D., Miller, H. E., Guleria, I., Barth, R. J., Huang, Y. H., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420370112 · Cited by 374
Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors
van den Broek, M. F., Müller, U., Huang, S., Aguet, M., & Zinkernagel, R. M. (1995) · Journal of Virology · doi:10.1128/jvi.69.8.4792-4796.1995 · Cited by 363
Devarkar, S. C., Wang, C., Miller, M. T., Ramanathan, A., Jiang, F., Khan, A. G., Patel, S. S., & Marcotrigiano, J. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1515152113 · Cited by 357
Self-citationEpithelial–mesenchymal transition: a new target in anticancer drug discovery
Marcucci, F., Stassi, G., & De Maria, R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.13 · Cited by 342
DeKruyff, R. H., Bu, X., Ballesteros, A., Santiago, C., Chim, Y.-L. E., Lee, H.-H., Karisola, P., Pichavant, M., Kaplan, G. G., Umetsu, D. T., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903059 · Cited by 330
Schuberth-Wagner, C., Ludwig, J., Bruder, A. K., Herzner, A.-M., Zillinger, T., Goldeck, M., Schmidt, T., Schmid-Burgk, J. L., Kerber, R., Wolter, S., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.06.015 · Cited by 311
Immune Defence in Mice Lacking Type I and/or Type II Interferon Receptors
VAN DEN BROEK, M. F., MULLER, U., HUANG, S., ZINKERNAGEL, R. M., & AGUET, M. (1995) · Immunological Reviews · doi:10.1111/j.1600-065x.1995.tb00090.x · Cited by 306
Kohlhapp, F. J., & Kaufman, H. L. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2667 · Cited by 303
CD40 stimulation obviates innate sensors and drives T cell immunity in cancer
Byrne, K. T., & Vonderheide, R. H. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.058 · Cited by 282 · cited 1×
“Using a mouse pancreatic cancer model, an agonist CD40 antibody was shown to bypass the typical requirement for innate sensors, including cGAS/STING and TLRs, and mount immune-mediated rejection when combined with chemotherapy (Byrne and Vonderheide, 2016).”
BackgroundGlodde, N., Bald, T., van den Boorn-Konijnenberg, D., Nakamura, K., O’Donnell, J. S., Szczepanski, S., Brandes, M., Eickhoff, S., Das, I., Shridhar, N., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.09.012 · Cited by 277
Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
Garg, A. D., More, S., Rufo, N., Mece, O., Sassano, M. L., Agostinis, P., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1386829 · Cited by 276
Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling
Minn, A. J., & Wherry, E. J. (2016) · Cell · doi:10.1016/j.cell.2016.03.031 · Cited by 271
Self-citationAn Overview of Novel Adjuvants Designed for Improving Vaccine Efficacy
Bonam, S. R., Partidos, C. D., Halmuthur, S. K. M., & Muller, S. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.06.002 · Cited by 261
Viral unmasking of cellular 5S rRNA pseudogene transcripts induces RIG-I-mediated immunity
Chiang, J. J., Sparrer, K. M. J., van Gent, M., Lässig, C., Huang, T., Osterrieder, N., Hopfner, K.-P., & Gack, M. U. (2018) · Nature Immunology · doi:10.1038/s41590-017-0005-y · Cited by 259
Katlinski, K. V., Gui, J., Katlinskaya, Y. V., Ortiz, A., Chakraborty, R., Bhattacharya, S., Carbone, C. J., Beiting, D. P., Girondo, M. A., Peck, A. R., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.01.004 · Cited by 248
The innate immune system, toll-like receptors and dermal wound healing: A review
Portou, M. J., Baker, D., Abraham, D., & Tsui, J. (2015) · Vascular Pharmacology · doi:10.1016/j.vph.2015.02.007 · Cited by 236
Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes
Zhu, J., Powis de Tenbossche, C. G., Cané, S., Colau, D., van Baren, N., Lurquin, C., Schmitt-Verhulst, A.-M., Liljeström, P., Uyttenhove, C., & Van den Eynde, B. J. (2017) · Nature Communications · doi:10.1038/s41467-017-00784-1 · Cited by 230
Sanmamed, M. F., Pastor, F., Rodriguez, A., Perez-Gracia, J. L., Rodriguez-Ruiz, M. E., Jure-Kunkel, M., & Melero, I. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.014 · Cited by 190
Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs
Ranoa, D. R. E., Parekh, A. D., Pitroda, S. P., Huang, X., Darga, T., Wong, A. C., Huang, L., Andrade, J., Staley, J. P., Satoh, T., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8420 · Cited by 183
Toll-Like Receptor 4 Has an Essential Role in Early Skin Wound Healing
Chen, L., Guo, S., Ranzer, M. J., & DiPietro, L. A. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.267 · Cited by 181
Pattern recognition receptors: immune targets to enhance cancer immunotherapy
Shekarian, T., Valsesia-Wittmann, S., Brody, J., Michallet, M. C., Depil, S., Caux, C., & Marabelle, A. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx179 · Cited by 181
Wang, Y., Swiecki, M., Cella, M., Alber, G., Schreiber, R. D., Gilfillan, S., & Colonna, M. (2012) · Cell Host & Microbe · doi:10.1016/j.chom.2012.05.003 · Cited by 172
Blockade of Interferon Beta, but Not Interferon Alpha, Signaling Controls Persistent Viral Infection
Ng, C. T., Sullivan, B. M., Teijaro, J. R., Lee, A. M., Welch, M., Rice, S., Sheehan, K. C. F., Schreiber, R. D., & Oldstone, M. B. A. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2015.04.005 · Cited by 172
Apoptotic Cells Induced Signaling for Immune Homeostasis in Macrophages and Dendritic Cells
Trahtemberg, U., & Mevorach, D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01356 · Cited by 132
Lin, Q., Fang, D., Fang, J., Ren, X., Yang, X., Wen, F., & Su, S. B. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003007 · Cited by 125
Sistigu, A., Modugno, F. D., Manic, G., & Nisticò, P. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.05.008 · Cited by 110
TLR4, rather than TLR2, regulates wound healing through TGF-β and CCL5 expression
Suga, H., Sugaya, M., Fujita, H., Asano, Y., Tada, Y., Kadono, T., & Sato, S. (2013) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2013.10.009 · Cited by 109
Immune Promotion of Epithelial-mesenchymal Transition and Generation of Breast Cancer Stem Cells
Reiman, J. M., Knutson, K. L., & Radisky, D. C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4041 · Cited by 106
Mechanisms of epithelial wound detection
Enyedi, B., & Niethammer, P. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.02.007 · Cited by 102
Bystander Chronic Infection Negatively Impacts Development of CD8+ T Cell Memory
Stelekati, E., Shin, H., Doering, T. A., Dolfi, D. V., Ziegler, C. G. K., Beiting, D. P., Dawson, L. A., Liboon, J., Wolski, D., Ali, M.-A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.04.010 · Cited by 101
Lin, Q., Wang, L., Lin, Y., Liu, X., Ren, X., Wen, S., Du, X., Lu, T., Su, S. Y., Yang, X., et al. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.120 · Cited by 92
Hamilton, D. H., Huang, B., Fernando, R. I., Tsang, K.-Y., & Palena, C. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1894 · Cited by 84
Gerner, M. Y., Heltemes-Harris, L. M., Fife, B. T., & Mescher, M. F. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300652 · Cited by 82
Sato, T., Yamamoto, M., Shimosato, T., & Klinman, D. M. (2010) · Wound Repair and Regeneration · doi:10.1111/j.1524-475x.2010.00632.x · Cited by 75
Muraro, E., Furlan, C., Avanzo, M., Martorelli, D., Comaro, E., Rizzo, A., Faè, D. A., Berretta, M., Militello, L., Conte, A. D., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01476 · Cited by 75
Fine-tuning T cell receptor signaling to control T cell development
Fu, G., Rybakin, V., Brzostek, J., Paster, W., Acuto, O., & Gascoigne, N. R. J. (2014) · Trends in Immunology · doi:10.1016/j.it.2014.05.003 · Cited by 72
A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells
Singer, M., Wang, C., Cong, L., Marjanovic, N. D., Kowalczyk, M. S., Zhang, H., Nyman, J., Sakuishi, K., Kurtuluş, S., Gennert, D. G., et al. (2017) · Cell · doi:10.1016/j.cell.2017.11.006 · Cited by 71
Purbey, P. K., Scumpia, P. O., Kim, P. J., Tong, A.-J., Iwamoto, K. S., McBride, W. H., & Smale, S. T. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.017 · Cited by 66
Zhang, T., Yu, H., Ni, C., Zhang, T., Liu, L., Lv, Q., Zhang, Z., Wang, Z., Wu, D., Wu, P., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-04978-x · Cited by 58
Hochheiser, K., Klein, M., Gottschalk, C., Hoß, F., Scheu, S., Coch, C., Hartmann, G., & Kurts, C. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501958 · Cited by 53
New insights into type I interferon and the immunopathogenesis of persistent viral infections
Snell, L. M., & Brooks, D. G. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.03.002 · Cited by 48
Radiation and Immune Checkpoint Blockade: From Bench to Clinic
Shabason, J. E., & Minn, A. J. (2017) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2017.03.002 · Cited by 44
Self-citationPrimary sterile necrotic cells fail to cross-prime CD8+T cells
Gamrekelashvili, J., Ormandy, L. A., Heimesaat, M. M., Kirschning, C. J., Manns, M. P., Korangy, F., & Greten, T. F. (2012) · OncoImmunology · doi:10.4161/onci.21098 · Cited by 36
Charlebois, R., Allard, B., Allard, D., Buisseret, L., Turcotte, M., Pommey, S., Chrobák, P., & Stagg, J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1873 · Cited by 30
T ‐cell exhaustion due to persistent antigen: Quantity not quality?
Zúñiga, E. I., & Harker, J. A. (2012) · European Journal of Immunology · doi:10.1002/eji.201242852 · Cited by 27
Cited by
Tumour-intrinsic resistance to immune checkpoint blockade
Kalbasi, A., & Ribas, A. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0218-4 · Cited by 1,486
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
Bianchini, G., De Angelis, C., Licata, L., & Gianni, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00565-2 · Cited by 1,382
The lung microenvironment: an important regulator of tumour growth and metastasis
Altorki, N. K., Markowitz, G. J., Gao, D., Port, J. L., Saxena, A., Stiles, B., McGraw, T., & Mittal, V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-018-0081-9 · Cited by 1,150
Dijkstra, K. K., Cattaneo, C. M., Weeber, F., Chalabi, M., van de Haar, J., Fanchi, L. F., Slagter, M., van der Velden, D. L., Kaing, S., Kelderman, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.009 · Cited by 1,135
“In addition to the analysis of natural and therapy-induced variation in tumor cell sensitivity to T cell pressure, there is increasing interest in the use of small molecules and antibodies to enhance tumor cell sensitivity to T cell attack (Patel and Minn, 2018).”
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Dhatchinamoorthy, K., Colbert, J. D., & Rock, K. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.636568 · Cited by 1,077
Metadata
- Authors
- Patel, S. A., & Minn, A. J.
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 48
- Issue
- 3
- Pages
- 417-433
- ISSN
- 1074-7613 (ISSN-L)
- OpenAlex
- W2794137041
- Cited by
- 573
- References
- 173
- FWCI
- 22.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.